FORM	4
------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address of Reporting Person [*] RINGROSE PETER S		2. Issuer Name and RIGEL PHARMA		-		RIGL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner					
(Last) (First) RIGEL PHARMACEUTICALS, INC. VETERANS BLVD.	1100	3. Date of Earliest Transaction (Month/Day/Year) 02/02/2005						Officer (give title below)Oth	er (specify below	w)		
(Street) SOUTH SAN FRANCISCO, CA 9408		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acqu						quired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
		(Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	1		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Conversion	Date (Month/Day/Year)	Execution Date, if	Code	tion)	5. Numbo of Deriva Securities Acquired or Dispos of (D) (Instr. 3, and 5)	tive s (A) sed	6. Date Exercisable and Expiration Date (Month/Day/Year)		e and 7. Title and Amount of Underlying			Securities Beneficially Owned Following Reported Transaction(s)	y Ownership Form of Derivative Security: Direct (D) or Indirect n(s) (I)	Beneficial
				Code	v	(A)		Exercisable	Expiration Date		Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 19.3	02/02/2005		А		13,333		03/02/2005 ⁽¹⁾	02/02/2015	Common Stock	13,333	\$ 0	13,333	D	
Stock Option (Right to Buy)	\$ 19.3	02/02/2005		А		6,667		03/02/2005(1)	02/02/2015	Common Stock	6,667	\$ 0	6,667	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
RINGROSE PETER S RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	Х						

Signatures

/s/ James H. Welch (Attorney-in-Fact)	02/04/2005
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

(1) Shares vest equally over twenty-four (24) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).